ClinicalTrials.Veeva

Menu
M

Mid Atlantic Retina Specialists | Hagerstown, MD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aflibercept
APL-2
Axitinib
Sunitinib Malate
GB-102
Bevacizumab
Runcaciguat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 12 total trials

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Enrolling
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Active, not recruiting
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2
Locations recently updated

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

Enrolling
Neovascular Age-related Macular Degeneration
Drug: OTX-TKI
Drug: Aflibercept

Trial sponsors

Jaeb Center for Health Research logo
A
Bayer logo
AbbVie logo
C
G
Ocular Therapeutix logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems